Abstract
In order to sustain an acquired immunodeficiency syndrome (AIDS) drug azidothymidine (AZT) in high level in the blood, novel AZT prodrugs, i.e., AZT-bound sulfated laminaripentaose and AZT-bound sulfated alkyl laminaripentaosides, were synthesized. AZT was introduced into the backbone of laminaripentaose and alkyl laminaripentaoside through biodegradable ester bond to give AZT-bound laminaripentaose and AZT-bound alkyl laminaripentaoside, respectively. Subsequently, they were sulfated with SO3-pyridine complex to produce AZT-bound sulfated laminaripentaose and AZT-bound sulfated alkyl laminaripentaoside. Their anti-Human Immunodeficiency Virus (HIV) activities were assayed in vitro by use of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) method. It was revealed that AZT-bound sulfated laminaripentaose exhibited much higher anti-HIV activity (EC50=0.20 μg ml−1) than AZT-free sulfated laminaripentaose (EC50=160 μg ml−1) even when AZT was not released from sulfated laminaripentaose, and a low cytotoxicity of CC50 above 1000 μg ml−1. Moreover, an alkyl group combined to the reducing end of AZT-bound sulfated alkyl laminaripentaoside increased the anti-HIV activity further (EC50=0.04–0.23 μg ml−1). In addition, AZT-bound sulfated alkyl laminaripentaoside possessed a very low or undetectable anticoagulant activity.
Similar content being viewed by others
Article PDF
References
H. Mitsuya, K. J. Weinhole, P. A. Furman, M. H. St Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder, Proc. Natl. Acad. Sci. U.S.A., 82, 7096 (1985).
H. Mitsuya, Proc. Natl. Acad. Sci. U.S.A., 84, 2033 (1987).
H. Mitsuya and S. Broder, Proc. Natl. Acad. Sci. U.S.A., 83, 1911 (1986).
B. A. Larder, S. D. Kemp, and P. R. Harrigan, Science, 269, 696 (1995).
X. Wei, S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw, Nature, 373, 117 (1995).
D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz, Nature, 373, 123 (1995).
C. Tamalet, A. Lafeuillade, J. Fantini, C. Poggi, and N. Yahi, AIDS, 11, 895 (1997).
R. W. Klecker, J. M. Collins, R. Yarchoan, R. Thoma, J. F. Jenkins, S. Broder, and C. E. Meyers, Clin. Pharmacol. Ther., 41, 407 (1987).
M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, and D. King, New Engl. J. Med., 317, 185 (1987).
D. D. Richman, M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, G. G. Jackson, D. T. Durack, and S. Nusinoff-Lehrman, New Engl. J. Med., 317, 192 (1987).
E. De Clercq, J. Med. Chem., 29, 1561 (1986).
M. Baba, D. Schols, R. Pauwels, H. Nakashima, E. and De Clercq, J. Acquired Immunodeficiency Syndromes, 3, 493 (1990),
M. Holodniy, S. Kim, D. Katzenstein, M. Konrad, E. Groves, and T. C. Merigan, J. Clin. Microbiol., 29, 676 (1991).
T. Moriya, H. Kurita, K. Matsumoto, T. Otake, H. Mori, M. Morimoto, N. Ueba, and N. Kunita, J. Med. Chem., 34, 2301 (1991).
E. Mbemba, V. Chams, J. C. Gluckman, D. Klatzmann, and L. Gattegno, Biochim. Biophys. Acta, 1138, 62 (1992).
J. Neyts, D. Reymen, D. Letourneur, J. Jozefonvicz, D. Schols, J. Este, G Andrei, P. McKenna, M. Witvrouw, S. Ikeda, J. Clement, and E. De Clercq, Biochem. Pharmacol., 50, 743 (1995).
K. Hatanaka, T. Yoshida, T. Uryu, O. Yoshida, H. Nakashima, N. Yamamoto, T. Mimura, and Y. Kaneko, Jpn. J. Cancer Res., 80, 95 (1989).
Y. Kaneko, O. Yoshida, R. Nakagawa, T. Yoshida, M. Date, S. Ogihara, T. Shioya, Y. Matsuzawa, H. Shinkai, N. Yasuda, K. Matsuzaki, T. Uryu, and N. Yamamoto, Biochem. Pharmacol., 25, 163 (1990).
T. Yoshida, K. Hatanaka, T. Uryu, Y. Kaneko, E. Suzuki, H. Miyano, T. Mimura, O. Yoshida, and N. Yamamoto, Macromolecules, 23, 3717 (1990).
M. Gordon, M. Guralnik, Y. Kaneko, T. Mimura, M. Baker, and W. Lang, J. Med., 25, 163 (1994).
T. Uryu, N. Ikushima, K. Katsuraya, T. Shoji, N. Takahashi, T. Yoshida, K. Kanno, T. Murakami, H. Nakashima, and N. Yamamoto, Biochem. Pharmacol., 43, 2385 (1992).
K. Katsuraya, N. Ikushima, N. Takahashi, T. Shoji, H. Nakashima, N. Yamamoto, T. Yoshida, and T. Uryu, Carbonhydr. Res., 260, 51 (1994).
K. Katsuraya, T. Shoji, K. Inazawa, H. Nakashima, N. Yamamoto, and T. Uryu, Macromolecules, 27, 6695 (1994).
H. Nakashima, K. Inazawa, K. Ichiyama, M. Ito, N. Ikushima, T. Shoji, K. Katsuraya, T. Uryu, N. Yamamoto, A. S. Juodawlkis, and R. F. Schinazi, Antiviral Chem. Chemother., 6, 271 (1995).
Y. Gao, K. Katsuraya, Y. Kaneko, T. Mimura, H. Nakashima, and T. Uryu, Polym. J., 30, 31 (1998).
R. Pauwels, J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq, J. Virol. Methods, 20, 309 (1988).
K. Hatanaka, T. Yoshida, S. Miyahara, T. Sato, F. Ono, T. Uryu, and H. Kuzuhara, J. Med. Chem., 30, 810 (1987).
K. Katsuraya and T. Uryu, to be submitted.
T. Kawaguchi, K. Ishikawa, T. Seki, and K. Juni, J. Pharm. Sci., 79, 531 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gao, Y., Katsuraya, K., Kaneko, Y. et al. Synthesis of Azidothymidine-Bound Sulfated Alkyl Oligosaccharides and Their Inhibitory Effects on AIDS Virus Infection in vitro. Polym J 30, 243–248 (1998). https://doi.org/10.1295/polymj.30.243
Issue Date:
DOI: https://doi.org/10.1295/polymj.30.243
Keywords
This article is cited by
-
Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics
Pharmaceutical Research (2018)
-
Ester Derivatives of Nucleoside Inhibitors of Reverse Transcriptase: 2. Molecular Systems for the Combined Therapy with 3′-Azido-3′-Deoxythymidine and 2′,3′-Didehydro-3′-Deoxythymidine
Russian Journal of Bioorganic Chemistry (2005)